A Clinical Trial of Lurasidone in Treatment of Schizophrenia

Phase 3CompletedNCT02002832

Marubeni Pharmaceuticals (Suzhou) Co., Ltd.388 enrolled

Overview

This is a randomized, double-blind, double-dummy, parallel- controlled, adjustable dose, non-inferiority and multicentre study designed to evaluate the efficacy and safety of lurasidone on schizophrenia for 6 weeks treatment, and to compare with risperidone.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

388

Conditions

Schizophrenia

Interventions

Lurasidone tabletsDRUG

Lurasidone tablets (40or80mg/day) and Risperidone tablets(Placebo)

Risperidone tabletsDRUG

Risperidone tablets(2-6mg/day) and Lurasidone tablets(Placebo)

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Provide written informed consent and aged between 18 and 65 years of age. * Meets DSM-IV-TR criteria for a primary diagnosis of schizophrenia, had a PANSS total score ≥ 70 and ≤ 120 at Screening and Baseline, and a score ≥ 4 on the CGI-S at Screening and Baseline. * Not pregnant, if of reproductive potential agrees to use adequate and reliable contraception for duration of study. * Able and agrees to remain off prior antipsychotic medication for the duration of study. * Willing and able to comply with the protocol, including the inpatient requirements and outpatient visits. Exclusion Criteria: * Considered by the investigator to be at imminent risk of suicide or injury to self, others or property. * Any chronic organic disease of the CNS(other than schizophrenia) * Subjects are participating or participated in other clinical studies including marketed drugs or medical devices within 30 days before signing the informed consent form. * Clinically significant or history of alcohol abuse/alcoholism or drug abuse/dependence within the last 6 months.

Locations (15)

Capital Medical University Affiliated Beijing Anding Hospital

Beijing, Beijing Municipality, China

Beijing Huilongguan Hospital

Beijing, Beijing Municipality, China

Outcomes

Primary Outcomes

Mean Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Scores.

Mean change in Positive and Negative Syndrome Scale total score from baseline to Week 6 at the end of treatment. PANSS is an interview-based measure of the severity of psychopathology in adults with psychotic disorders. It have 30 evaluation items, which include 7 positive sub-scale, 7 negative sub-scale and 16 general psychopathology sub-scale on a score of 1 to 7. The total score is the sum of the 30 scale items. The minimum score is 30 and the maximum score is 210. Patient with PANSS total scores\<70 is the normal,but the scores\>120 is more serious.

Time frame: From baseline to Week 6(day 42).

Secondary Outcomes

Mean Clinical Global Impression Scale-Improvement (CGI-I) Score at Week 6.

The Clinical Global Impression Scale-Improvement (CGI-I) Score is a 7 point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to baseline state at the beginning of the intervention. Response is rated as one of the following, in which higher scores indicate less improvement or worsening: 1=Very much improved, 2=Much improved, 3=Minimally improved, 4=No change, 5=Minimally worse, 6=Much worse, and 7=Very much worse.

Time frame: From baseline to Week 6(day 42).

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.